INVO BioScience, Inc.

As of May 15, 2023, INVO BioScience, Inc. is considered risky and overvalued due to significant losses, reflected in poor valuation metrics and a year-to-date stock performance decline of 97.01%, contrasting sharply with the S&P 500's positive return.

As of May 15, 2023, INVO BioScience, Inc. is considered overvalued and risky due to poor financial metrics, including a price to book value of 0.13, negative ROCE of -69.23%, and negative ROE of -139.69%, indicating significant inefficiencies compared to its peers.

As of June 11, 2025, the market trend has shifted to bearish, with key indicators like daily moving averages and Bollinger Bands confirming this outlook, despite a mildly bullish MACD on longer time frames.

INVO BioScience, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, reporting net sales of $2 million and a net loss of $17 million as of March 2025. It has a market cap of $2.70 million and key metrics indicate a negative return on equity and no dividend yield.

As of Jun 18, INVO BioScience, Inc. has a market capitalization of 2.70 million, with net sales of 6.60 million and a net profit of -24.90 million over the last four quarters. The company's shareholder's funds are 12.75 million, and total assets amount to 46.45 million.